Antidepressant and neurocognitive effects of serial ketamine administration versus ECT in depressed patients

Basso, Laura; Bönke, Luisa; Aust, Sabine; Gärtner, Matti; Heuser-Collier, Isabella; Otte, Christian; Wingenfeld, Katja; Bajbouj, Malek; Grimm, Simone

doi:10.1016/j.jpsychires.2020.01.002

Cited by 48 publications

(31 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings are partially in consonance with previous reports on the lack of deleterious neurocognitive effect of single or repeated ketamine 12,13,[34][35][36] beyond its acute CNS side effects. While speed of procession, set-shifting, complex working memory and visual memory improved in the six ketamine group, verbal memory and speed of processing decreased after six and single infusions, respectively.…”

Section: Discussionsupporting

confidence: 93%

Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression

Shiroma

Thuras

Wels

et al. 2020

Journal of Affective Disorders

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Discussionsupporting

confidence: 93%

Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression

Shiroma

Thuras

Wels

et al. 2020

Journal of Affective Disorders

View full text Add to dashboard Cite

show abstract

“…24 In this regard, educational interventions have been demonstrated to improve awareness and attitudes toward ECT. 29,30 Further, we observed that almost all participants (97.3%) were unaware of TMS. The effect size for TMS is largely beneficial and is recommended for the treatment-resistant or treatment-intolerant patients with depression.…”

Section: Risk Factors Related To the Development Of Depressionmentioning

confidence: 72%

Public awareness, beliefs and attitude towards depressive disorders in Saudi Arabia

Aljadani

Alshammari

et al. 2021

SMJ

View full text Add to dashboard Cite

Objectives: To investigate the degree of public awareness, beliefs, and attitudes regarding major depression and available treatment options in the Saudi population. Methods:A community-based cross-sectional study of 1,188 participants was carried out from March to April 2021 in Ha'il, Saudi Arabia using an online self-administered questionnaire. Using a snowball sampling technique, the authors targeted the Saudi population living in Ha'il region.Results: Overall, 65.6% of the participants had good awareness regarding depression disorder in total. Of the participants, 72.9% had good awareness regarding Original Article general awareness, 85.4% regarding depression symptoms, 12.3% regarding risk factors, and 15.7% regarding treatments. Of the participants, 67.3% believed that depression was caused by lack of faith and 45.5% believed that depression was caused by "the evil eye" or black magic. Of the participants, 56% believed in faith healers as a legitimate treatment approach. Of the participants, 63.9% were willing to work with individuals with depression, 62.7% were willing to establish friendships with them, and 27.9% believed that individuals with depression had weak personalities. Conclusion:The general population exhibited good general awareness regarding depression and its symptoms, but knowledge of risk factors and treatments was poor. Our findings underscore the need for public educational programs to increase public awareness about the risk factors and treatment options for depression.

show abstract

“…Importantly, rapid and sustained improvements in suicidality have also been reported (Grunebaum et al, 2018;Sinyor et al, 2018;Domany et al, 2020), suggesting that ketamine might be useful in patients with suicidal ideation and behavior. The antidepressant effects of ketamine are comparable to those of electroconvulsive therapy but have faster onset (Basso et al, 2020). Importantly, greater adverse events can be encountered when ketamine is used instead of other anesthetics for electroconvulsive therapy (Yen et al, 2015;Carspecken et al, 2018).…”

Section: E Ketaminementioning

confidence: 99%

Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms

2020

View full text Add to dashboard Cite

Mounting evidence suggests safety and efficacy of psychedelic compounds as potential novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug Administration in a new class of antidepressants, and 3,4-methylenedioxymethamphetamine (MDMA) is undergoing phase III clinical trials for post-traumatic stress disorder. Psilocybin and lysergic acid diethylamide (LSD) are being investigated in several phase II and phase I clinical trials. Hence, the concept of psychedelics as therapeutics may be incorporated into modern society. Here, we discuss the main known neurobiological therapeutic mechanisms of psychedelics, which are thought to be mediated by the effects of these compounds on the serotonergic (via 5-HT 2A and 5-HT 1A receptors) and glutamatergic [via N-methyl-D-aspartate (NMDA) and a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors] systems. We focus on 1) neuroplasticity mediated by the modulation of mammalian target of rapamycin-, brain-derived neurotrophic factor-, and early growth response-related pathways; 2) immunomodulation via effects on the hypothalamic-pituitaryadrenal axis, nuclear factor ĸB, and cytokines such as tumor necrosis factor-a and interleukin 1, 6, and 10 204 Inserra et al.

show abstract

Antidepressant and neurocognitive effects of serial ketamine administration versus ECT in depressed patients

Cited by 48 publications

References 35 publications

Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression

Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression

Public awareness, beliefs and attitude towards depressive disorders in Saudi Arabia

Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms

Contact Info

Product

Resources

About